Lamivir Tablets (Generic Lamivudine Tablets)

© Clearsky Pharmacy ( www.clearskypharmacy.biz )
Lamivir Tablets (Generic Lamivudine Tablets)

are used in combination with other antiretroviral
agents for the treatment of HIV-1 infection.

Active Ingredient
The active ingredient present in Lamivir HBV
and Lamivir tablets is Lamivudine. Each
Lamivir tablet contains 150 mg of Lamivudine.

Chemical Structure
The structure of Lamivudine is given below:

Lamivir Tablets are manufactured by Cipla Limited, India
in the strength of 150 mg.
( Website: https://www.cipla.com/ )
URL: https://www.clearskypharmacy.biz/lamivudine-tablets.html

Lamivudine Tablets – Brand Names
Lamivudine tablets are available under
various drug trade names that include
Epivir-HBV, Epivir, Lamivir HBV, Lamivir,
Hepitec, Hepavud, Lamda, Lami, Lamidac,
Lamuvid, Retrolam, Viramid and Virolam.

Uses of Lamivir Tablets
Lamivir Tablets (Generic Lamivudine Tablets) are used in combination
with other medicines for the treatment of the infection caused by the
human immunodeficiency virus (HIV). HIV is the virus that causes
acquired immune deficiency syndrome (AIDS).
Lamivudine will not cure or prevent HIV infection or AIDS. It helps keep
HIV from reproducing and appears to slow down the destruction of the
immune system. This may help delay the development of serious health
problems usually related to AIDS or HIV disease from occurring.
Lamivudine will not keep you from spreading HIV to other people. People
who receive this medicine may continue to have other problems usually
related to AIDS or HIV disease.

Lamivir Tablets Dosage
The dosage of Lamivir tablets (Generic Lamivudine Tablets) is given
below:
The recommended dosage of Lamivir (Generic Lamivudine Tablets) in
HIV-1 infected adults is 300 mg daily, administered as either 150 mg
taken orally twice daily, or 300 mg taken orally once daily with or
without food.
If Lamivudine is administered to a patient infected with HIV-1 and HBV,
the dosage indicated for HIV-1 therapy should be used as part of an
appropriate combination regimen.
Patients with Renal Impairment: Dosing of Lamivir is adjusted in
accordance with renal function. Reduction of the dosage of is
recommended for patients with impaired renal function.

Contraindications
Lamivir Tablets are contraindicated in patients with a
hypersensitivity to Lamivudine or any other component of this
medication.

Storage Instructions
Lamivir Tablets (Generic Lamivudine
Tablets) have to be stored at controlled room
temperature i.e. from 20°C to 25°C (68°F to
77°F) with excursions permitted between 15°
to 30°C (59° to 86°F).
Keep this as well as all other medicines away
from children and pets.

Warnings
In pediatric patients with a history of prior antiretroviral nucleoside
exposure, a history of pancreatitis, or other significant risk factors for the
development of pancreatitis, Lamivudine should be used with caution.
Treatment with Lamivir should be stopped immediately if clinical signs,
symptoms, or laboratory abnormalities suggestive of pancreatitis occur.
Lactic acidosis and severe hepatomegaly with steatosis, including fatal
cases, have been reported with the use of nucleoside analogues alone or in
combination, including Lamivudine and other antiretrovirals.
Severe acute exacerbations of hepatitis: Reported in patients who are co-
infected with hepatitis B virus and HIV-1 and discontinued Lamivudine
(Lamivir tablets). Monitor hepatic function closely in these patients and, if
appropriate, begin anti-hepatitis B treatment.

Warnings
Patients with HIV-1 infection should receive only dosage forms of Lamivudine
Tablets appropriate for treatment of HIV-1.
Co-infected HIV-1/HBV Patients: Emergence of Lamivudine-resistant HBV variants
associated with lamivudine-containing antiretroviral regimens has been reported.
Emtricitabine should not be administered concomitantly with Lamivudine
containing products.
Hepatic decompensation (some fatal) has occurred in HIV-1/HCV co-infected
patients receiving Interferon and Ribavirin-based regimens.
Monitor for treatment-associated toxicities. Discontinue Lamivudine as medically
appropriate and consider dose reduction or discontinuation of Interferon Alfa,
Ribavirin, or both.
Immune reconstitution syndrome and redistribution/accumulation of body fat have
been reported in patients treated with combination antiretroviral therapy.

Lamivir Tablets Side Effects
The most common reported Lamivudine Tablets (Lamivir
Tablets) side effects with an incidence rate greater than
or equal to 15% in adults were headache, nausea, malaise
and fatigue, nasal signs and symptoms, diarrhea, and
cough.
The most common reported side effects with an incidence
rate greater than or equal to 15% in pediatric subjects
were fever and cough.

Overdose
There is no known specific treatment for overdose with Lamivudine
Tablets (Lamivir Tablets).
In case overdose occurs, the patient should be monitored and standard
supportive treatment applied as necessary.
Since a negligible amount of Lamivudine was removed via (4-hour)
hemodialysis, continuous ambulatory peritoneal dialysis, and automated
peritoneal dialysis, it is not known if continuous hemodialysis would
provide clinical benefit in a Lamivudine overdose event.

Lamivir Tablets During Pregnancy
Lamivudine Tablets (Lamivir Tablets) has been classified by the
US FDA as Pregnancy Category C.
This medicine should be used during pregnancy only if clinically
needed and the benefit outweighs the risk to the fetus.
Animal studies have failed to show evidence of teratogenicity.
While early embryolethality was observed in rabbit studies with
an exposure levels similar to human levels, this effect was not
observed in high-dose studies in rats. Placental transfer has been
observed in humans. There are no controlled data in human
pregnancy.

For more details on
Lamivir Tablets click here
Lamivir Tablets (Generic Lamivudine Tablets) by Cipla Limited, India.

Lamivir Tablets (Generic Lamivudine Tablets)

Recommended

Recommended

More Related Content

More from Clearsky Pharmacy

More from Clearsky Pharmacy (20)

Lamivir Tablets (Generic Lamivudine Tablets)